DataString Consulting Company Logo
DataString Consulting Company Logo
Fluciclovine F18 Market
Home»Recent Reports»Fluciclovine F18 Market

Fluciclovine F18 Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802157, Published - March 2025

Segmented in Product Variant (Injectable, Oral, Intravenous), Application (Diagnosis, Recurrence, Research, Others), Distribution Channel, End-User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Fluciclovine F18 Market Outlook

The market, for Fluciclovine f18 was estimated at $430.0 million in 2024; and it is anticipated to increase to $817.4 million by 2030 with projections indicating a growth to around $1.4 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 11.3% over the forecast period. Fluciclovine F18s importance in the field of imaging and radiology remains strong due to various factors driving its consistent demand; heightened awareness about health worldwide; the growing prevalence of Alzheimers and cancer; and the genetic predisposition of specific groups to these illnesses play a significant role in fuel this trend forward. Advanced diagnostic techniques and the increasing need for disease prognosis further solidify fluciclovine F18s continued relevance, in the healthcare sector.


Fluciclovine F18 is known as a radiotracer. Plays a crucial role in positron emission tomography (PET) scans used to diagnose and treat various conditions like cancer primarily. Its main role is to help identify and pinpoint prostate cancer cases which has led to an increased demand for it. The radiotracer has also been gaining recognition for its application in imaging the metabolism of amino acids, in brain tumors or cognitive issues over the recent years.


Market Size Forecast & Key Insights

2019
$430M2024
2029
$1.3B2034

Absolute Growth Opportunity = $824M

The Fluciclovine F18 market is projected to grow from $430.0 million in 2024 to $1.25 billion in 2034. This represents a CAGR of 11.3%, reflecting rising demand across Oncological Diagnostics, Pharmaceutical R&D and Neurological Research.

The Fluciclovine F18 market is set to add $824 million between 2024 and 2034, with manufacturer targeting Recurrence & Research Application projected to gain a larger market share.

With Rise in prostate cancer diagnoses, and Technological advancements in pet imaging, Fluciclovine F18 market to expand 192% between 2024 and 2034.

Opportunities in the Fluciclovine F18 Market

Rising Demand in Developed Countries

The need for f18 is anticipated to rise in countries such as the United States due, to their sophisticated healthcare infrastructure. Cutting edge medical services and increasing knowledge of the advantages of early cancer detection may boost the use of fluciclovine f18 in these areas.

Expanding Applications in Medical Imaging and Advances in PET Scanning

The untapped opportunities in the imaging field show promising growth potential for fluciclovine F18 due to its effectiveness in identifying recurring prostate cancer cases. Expanding its usage tos of cancers could improve its market standing. Additionally advancements in technology might boost the demand for F18 increasing its importance, in the imaging sector.

Fluciclovine F18 is a marker used in PET scans and is set to form important partnerships with PET scanner makers for integrated solutions. Innovations in the industry like merging MRI and PET technologies could lead to thorough scanning methods and play a major role, in boosting the market for Fluciclovine F18.

Growth Opportunities in North America and Europe

Europe Outlook

In Europe the growth of the F18 market is being driven by the increasing prevalence of cancer and a growing emphasis on early detection and preventive healthcare measures. The market is highly competitive. Dominated by well established pharmaceutical companies that are investing in cutting edge radioisotopes. The strong healthcare infrastructure and widespread awareness of cancer screening options have resulted in an uptake of fluciclovine F18. Supportive legislation for diagnostic methods and a notable rise in the elderly population further contribute to the increasing adoption of fluciclovine F18, in this region.

North America Outlook

In North America's fluciclovine f18 market is experiencing growth opportunities due to the increasing demand for better diagnostic solutions in the field of oncology. The market is being driven by the presence of pharmaceutical industry leaders technological advancements and higher healthcare spending. There is competition among key players who are focusing their efforts towards innovation and obtaining regulatory approvals for the use of fluciclovine f18 in diagnosing prostate cancer in pets. Additionally a favorable regulatory environment and a growing interest in medicine are further supporting the markets expansion, in this region.

North America Outlook

In North America's fluciclovine f18 market is experiencing growth opportunities due to the increasing demand for better diagnostic solutions in the field of oncology. The market is being driven by the presence of pharmaceutical industry leaders technological advancements and higher healthcare spending. There is competition among key players who are focusing their efforts towards innovation and obtaining regulatory approvals for the use of fluciclovine f18 in diagnosing prostate cancer in pets. Additionally a favorable regulatory environment and a growing interest in medicine are further supporting the markets expansion, in this region.

Europe Outlook

In Europe the growth of the F18 market is being driven by the increasing prevalence of cancer and a growing emphasis on early detection and preventive healthcare measures. The market is highly competitive. Dominated by well established pharmaceutical companies that are investing in cutting edge radioisotopes. The strong healthcare infrastructure and widespread awareness of cancer screening options have resulted in an uptake of fluciclovine F18. Supportive legislation for diagnostic methods and a notable rise in the elderly population further contribute to the increasing adoption of fluciclovine F18, in this region.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, Japan, France, United Kingdom are expected to grow at 8.2% to 11.9% CAGR

2

Emerging Markets : Brazil, South Korea, South Africa are expected to grow at 10.8% to 14.1% CAGR

Market Analysis Chart

Fluciclovine F18 is a radiotracer used in positron emission tomography scans that is making advancements in the field of medicine. Its primary application lies in detecting and treating prostate cancer whichs fuelinits increasing popularity in the healthcare industry. Nevertheless high expenses linked with PET scans and the restricted availability of imaging centers may pose challenges, for this expanding market segment.

Recent Developments and Technological Advancement

December 2024

Globatom Pharmaceuticals obtained the light from the FDA for their latest cancer diagnostic tool infused with fluciclovine F18. This approval has sparked growth in the fluciclovine F18 market.

October 2024

TurbineFarma utilized AI technologies to boost the large scale manufacturing of fluciclovine F18. This helped reduce costs and expanded access, to a wider range of consumers.

August 2024

MeridianHealth Inc., a biopharmaceutical company has revealed a significant funding allocation towards research and development of advanced uses for fluciclovine f18, in medical imaging.

In the realm of healthcare advancements lays Fluciclovine F18 – a diagnostic radiopharmaceutical well utilized in PET imaging procedures today for its precision and effectiveness, in identifying prostate cancer cases among patients.

Impact of Industry Transitions on the Fluciclovine F18 Market

As a core segment of the Pharmaceutical industry, the Fluciclovine F18 market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Digital Imaging and Expansion into New Therapeutic Areas have redefined priorities across the Pharmaceutical sector, influencing how the Fluciclovine F18 market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Emergence of Digital Imaging:

The advent of digital imaging technologies has left a significant impact on the fluciclovine f18 industry. With fluciclovine f18 PET imaging becoming more advanced, it has revolutionized the diagnostics field, particularly in the detection of recurrent prostate cancer. This technology combines the ability of fluciclovine f18 to target cancer cells with the precision of digital imaging. As a result, healthcare professionals can now identify the exact location and size of the tumor, improving the efficacy of treatment plans while minimizing the side effects.

2

Expansion into New Therapeutic Areas:

The fluciclovine f18 industry is moving towards investigating medical fields instead of just focusing on prostate cancer diagnosis as before​. Researchers are now looking into the effectiveness of fluciclovine f18 in detecting various cancers such as brain and ovarian cancer​. This shift opens up opportunities, for healthcare solutions by enabling early detection of a wider range of diseases​. Overall​ it enhances the potential to save lives through this innovative approach​.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Fluciclovine F18 market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rise in Prostate Cancer Diagnoses, and Increased Demand for Precision in Cancer Detection

The rising number of prostate cancer cases globally plays a role in the demand for fluciclovine f18, in the medical imaging field used to identify recurring prostate cancer cases more effectively and ultimately boosting the market share of fluciclovine f18.
The healthcare fields increasing focus on medicine in cancer diagnosis has also led to a rise in the use of fluciclovine f18, for its precise detection capabilities that enhance the identification of cancerous tissues and support tailored treatment strategies. Driving growth in the fluciclovine f18 sector.
In years there have also been notable improvements in PET imaging technology that have also included the use of fluciclovine f18 due to its accurate and low radiation properties which allow for safer and more precise detection of prostate cancer recurrence. The push for technology, in PET imaging is also anticipated to increase the utilization of fluciclovine f18 even more.

Restraint: Regulatory Challenges

The strict regulations in place pose a challenge to the fluciclovine f18 market segment used primarily for PET imaging procedures due to the need to meet quality and safety guidelines established by regulatory bodies such as the FDA. This leads to an costly process that can potentially hinder the drugs progression through development stages and approval processes while delaying its market introduction. Even a minor setback or failure to meet compliance standards could result in financial consequences that impede progress, in innovation and impact consumer demand adversely.

Challenge: Restricted Accessibility

While fluciclovine f18 shows promise in improving cancer detection methods its availability poses an obstacle. Access to centers with PET imaging tools and skilled staff is crucial for using fluciclovine f18 effectively but these resources are not only readily available everywhere. Areas with healthcare funding or those, in developing nations often lack these facilities thereby preventing a large portion of the worlds population from receiving its benefits.

Supply Chain Landscape

Raw Material Extraction

Positron Corporation

Pharmalogic PET Services

Chemical Synthesis

Blue Earth Diagnostics

Siemens Healthineers

Manufacturing & Formulation
GE Healthcare / Blue Earth Diagnostics
Distribution & End Users
Health Care Institutions / Diagnostic Centres / Pharmaceutical Companies
Raw Material Extraction

Positron Corporation

Pharmalogic PET Services

Chemical Synthesis

Blue Earth Diagnostics

Siemens Healthineers

Manufacturing & Formulation

GE Healthcare

Blue Earth Diagnostics

Distribution & End Users

Health Care Institutions

Diagnostic Centres

Pharmaceutical Companies

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Oncology
Medical and Healthcare
Blue Earth Diagnostics
Focus on high precision detection of cancerous cell growth and metastases
Neurology
Medical and Healthcare
Nihon Medi-Physics
Development of advanced diagnostics tools for neurogenerative diseases
Cardiology
Medical and Healthcare
Siemens Healthineers
Integration of artificial intelligence for precise cardiovascular diagnosis

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Fluciclovine F18 market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Fluciclovine F18 in Neurological Research, Pharmaceutical R&D and Oncological Diagnostics

Neurological Research

Fluciclovine f18 has demonstrated promise in the field of neurological research by showcasing a unique ability to either penetrate or be blocked by the blood brain barrier depending on various factors. This property is being extensively utilized in the investigation of brain conditions like Alzheimers and epilepsy with Siemens Healthineers leading the way in leveraging its features for advancements, in neurological research.

Pharmaceutical R&D

The field of research and development also benefits greatly from the use of fluciclovine f18 as a radioactive biomarker in the creation of new medications due to its distinct characteristics and capabilities. Its specific attributes allow it to offer information on how a new drug behaves in the body and its effects, on the body aiding in the creation of safer and more efficient drug development plans.

Oncological Diagnostics

In the field of cancer diagnostics in oncology Using the positron emission tomography Fluciclovine F18 is commonly employed as an imaging agent It plays a role in identifying recurring prostate cancer This detection is vital, for planning specific treatment approaches The radioactive tracer form of Fluciclovine F18 is utilized here Once injected into the body it collects in cancer cells This accumulation enables visualization of these cells during a PET scan Blue Earth Diagnostics stands out in the market as a player known for their expertise in using molecular imaging, for cancer detection.

Fluciclovine F18 vs. Substitutes:
Performance and Positioning Analysis

Fluciclovine F18 stands distinctively in the market due to its enhanced diagnostic accuracy for prostate cancer detection, compared to alternatives like carbon-11 choline. Its unique market positioning anticipates potential robust growth, leveraging the rising global cancer prevalence. These Alternatives specially Piflufolastat F 18 has experienced a rapid growth as detailed in our latest report.

Fluciclovine F18
  • Choline C 11 /
  • Gallium Ga 68 PSMA 11 /
  • Piflufolastat F 18
    High sensitivity in detecting recurrent prostate cancer, improved diagnostic capabilities compared to traditional imaging techniques
    Limited availability, high cost of production
    High sensitivity, specificity, and diagnostic performance
    High costs, limited availability, and potential for allergic reactions

Fluciclovine F18 vs. Substitutes:
Performance and Positioning Analysis

Fluciclovine F18

  • High sensitivity in detecting recurrent prostate cancer, improved diagnostic capabilities compared to traditional imaging techniques
  • Limited availability, high cost of production

Choline C 11 / Gallium Ga 68 PSMA 11 / Piflufolastat F 18

  • High sensitivity, specificity, and diagnostic performance
  • High costs, limited availability, and potential for allergic reactions

Fluciclovine F18 stands distinctively in the market due to its enhanced diagnostic accuracy for prostate cancer detection, compared to alternatives like carbon-11 choline. Its unique market positioning anticipates potential robust growth, leveraging the rising global cancer prevalence. These Alternatives specially Piflufolastat F 18 has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Fluciclovine F18 market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Fluciclovine F18 across Hospitals, Diagnostic Centers, and Research Institutions Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Blue Earth Diagnostics, Nihon Medi-Physics, and Siemens Healthineers by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Extraction, Chemical Synthesis, and Manufacturing & Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Fluciclovine F18 segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Extraction (Positron Corporation, Pharmalogic PET Services), Chemical Synthesis (Blue Earth Diagnostics, Siemens Healthineers), and Manufacturing & Formulation. Our parallel substitute analysis examines Choline C 11, Gallium Ga 68 PSMA 11, and Piflufolastat F 18, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Blue Earth Diagnostics, Nihon Medi-Physics, and Siemens Healthineers, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Fluciclovine F18 market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Fluciclovine F18 Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 478 million
Revenue Forecast in 2034USD 1.25 billion
Growth RateCAGR of 11.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024430 million
Growth OpportunityUSD 824 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024430 million USD
Market Size 2027592 million USD
Market Size 2029734 million USD
Market Size 2030817 million USD
Market Size 20341.25 billion USD
Market Size 20351.40 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredProduct Variant, Application, Distribution Channel, End-User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledBlue Earth Diagnostics, Nihon Medi-Physics, Siemens Healthineers, Lantheus Medical Imaging, Curium, Cardinal Health, IBA Molecular, Novartis, PETNET Solutions, Jubilant DraxImage, Advanced Accelerator Applications and GE Healthcare.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Fluciclovine F18 Market Size, Opportunities & Strategic Insights, by Product Variant

4.1Injectable
4.2Oral
4.3Intravenous
Chapter 5

Fluciclovine F18 Market Size, Opportunities & Strategic Insights, by Application

5.1Diagnosis
5.2Recurrence
5.3Research
5.4Others
Chapter 6

Fluciclovine F18 Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Pharmacies
6.2Direct Sales
6.3Online Platforms
Chapter 7

Fluciclovine F18 Market Size, Opportunities & Strategic Insights, by End-User

7.1Hospitals
7.2Diagnostic Centers
7.3Research Institutions
7.4Others
Chapter 8

Fluciclovine F18 Market, by Region

8.1North America Fluciclovine F18 Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Fluciclovine F18 Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Fluciclovine F18 Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Fluciclovine F18 Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Fluciclovine F18 Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Fluciclovine F18 Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Blue Earth Diagnostics
9.2.2Nihon Medi-Physics
9.2.3Siemens Healthineers
9.2.4Lantheus Medical Imaging
9.2.5Curium
9.2.6Cardinal Health
9.2.7IBA Molecular
9.2.8Novartis
9.2.9PETNET Solutions
9.2.10Jubilant DraxImage
9.2.11Advanced Accelerator Applications
9.2.12GE Healthcare.